Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.

Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia February 12, 2026 8:00 ...

Currently, the price of Bitcoin is putting the patience of investors to the test as it trades close to the $69,000 mark after ...

Earlier this week, UK advertising trade body the IPA released its latest Agency Census, with yet more evidence of widespread ...

The crypto market recently faced a downward trend, yet specific assets are demonstrating resilience. Zcash is a primary ...

You don’t need a perfect plan to get started with AI; you need a simple 90‑day path that fits around real life and real work. This roadmap is designed for professionals who are busy, a bit overwhelmed ...

Xylem Inc. (NYSE:XYL) Q4 2025 Earnings Call Transcript February 10, 2026 Xylem Inc. misses on earnings expectations. Reported EPS is $1.37 EPS, expectations were $1.42. Operator: Good day, everyone, ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended ...

Thursday, November 7, 2024 at 8:30 a.m. ET Revenue growth -- 10.9% year over year with 9.6% constant currency growth, led by accelerated volume gains. Volume growth -- 13% year over year with every ...

Thomas Frank took over at Tottenham after they won the Europa League. Now he's been fired with the club close to relegation.

The two companies and market darling Pro Medicus reset expectations for what it is like to get hammered on results day.

DXY slips to 96.80 despite strong NFP as weak retail sales weigh. CPI and jobless claims now key for GBP/USD and EUR/USD ...